- Home
- TCBI vs ELVN Comparison
TCBI vs ELVN Comparison
Compare TCBI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBI | ELVN |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.2B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCBI | ELVN |
|---|---|---|
| Price | $99.05 | $54.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $100.92 | $43.40 |
| AVG Volume (30 Days) | 360.2K | ★ 783.2K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 430.47 | 3.17 |
| EPS | ★ 3.39 | N/A |
| Revenue | ★ $149,000.00 | N/A |
| Revenue This Year | $14.76 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | $28.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $75.41 | $14.79 |
| 52 Week High | $108.92 | $62.32 |
Technical Indicators
Market Signals| Indicator | TCBI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 41.82 |
| Support Level | $97.30 | $25.63 |
| Resistance Level | $102.57 | $62.16 |
| Average True Range (ATR) | 1.62 | 1.95 |
| MACD | 0.10 | -0.59 |
| Stochastic Oscillator | 74.58 | 1.93 |
Price Performance
Historical ComparisonAbout TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.